OC
VYGR icon

Oppenheimer & Co’s Voyager Therapeutics VYGR Stock Holding History

Oppenheimer & Co’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,485
Closed -$169K – 1323
2020
Q1 		$169K Buy
18,485
+1,256
+7% +$14.4K 0.01% 1055
2019
Q4 		$240K Buy
17,229
+7
+0% +$102 0.01% 1108
2019
Q3 		$296K Sell
17,222
-523
-3% -$11K 0.01% 986
2019
Q2 		$483K Sell
17,745
-4
-0% -$92 0.01% 830
2019
Q1 		$339K Buy
17,749
+68
+0.4% +$886 0.01% 979
2018
Q4 		$166K Sell
17,681
-6,157
-26% -$79K 0.01% 1133
2018
Q3 		$452K Buy
23,838
+1,838
+8% +$35.3K 0.01% 902
2018
Q2 		$430K Buy
22,000
+6,000
+38% +$119K 0.01% 926
2018
Q1 		$301K Hold
16,000
– – 0.01% 1055
2017
Q4 		$266K Sell
16,000
-1,365
-8% -$23.4K 0.01% 1108
2017
Q3 		$357K Buy
17,365
+1,365
+9% +$15.4K 0.01% 967
2017
Q2 		$143K Buy
+16,000
New +$161K ﹤0.01% 1234

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Oppenheimer & Co's VYGR Position: Q2 2020 in Review

Oppenheimer & Co sold out of Voyager Therapeutics (VYGR) in Q2 2020, closing a stake of 18,485 shares — an estimated $169K sold.

Oppenheimer & Co first reported a position in VYGR in Q2 2017 and held it in 12 quarters. The position peaked at $483K in Q2 2019. 113 funds tracked by Wall St. Rank hold VYGR as of Q2 2020.

  • Oppenheimer & Co reported no remaining Voyager Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 18,485 Voyager Therapeutics shares in Q2 2020, an estimated $169K.
  • Oppenheimer & Co first reported a position in Voyager Therapeutics in Q2 2017 and held it in 12 quarters.
  • Oppenheimer & Co's Voyager Therapeutics position peaked at $483K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.